Clinical considerations in study designs that use cotinine as a biomarker

References

• AHN, H. C., YANG, J. H., LEE, H. B., RHEE, Y. K and LEE, Y. C. 2000, Effect of combined therapy of oral anti-tubercular agents on theophylline pharmacokinefics. International Journal of Tuberculosis and Lung Disease, 4 (8), 784–787.
   PubMed Web of Science ®Google Scholar
• ALDELAIMY, W. K. 2002, Hair as a biomarker for exposure to tobacco smoke. Tobacco Control, 11, 176–182.
   PubMed Web of Science ®Google Scholar
• APSELOFF, G., AstrroN, H., FRIEDMAN, H. and GERBER, N. 1994, The importance of measuring cotinine levels to identify smokers in clinical trials. Clinical Pharmacology and Therapeutics, 56 (4), 460–462.
   PubMed Web of Science ®Google Scholar
• BASELT, R. C. 1995, Disposition of Toxic Drugs and Chemicals in Man, 4th edition (Chicago: Year Book Medical Publishers), pp. 543–547.
   Google Scholar
• BENOWITZ, N. L. 1988, Pharmacologic aspects of cigarette smoking and nicotine addiction. New England Journal of Medicine, 319 (20), 1318–1330.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L. 1996, Cotinine as a biomaker of environmental tobacco smoke exposure. Epiclemiologic Reviews, 18 (2), 188–204.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L. and JACOB, P. 1993, Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clinical Pharmacology and Therapeutics, 53 (3), 316–323.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L. and JACOB, P. 2001, Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. British Journal of Clinical Pharmacology, 51, 53–59.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L, JACOB, P., JONES, R T and ROSENBERG, J. 1982, Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. Journal of Pharmacology and Experimental Therapeutics, 221 (2), 368–372.
   Google Scholar
• BENOWITZ, N. L, KuY-r, F., JACOB, P., JONES, R. T. and OSMAN, A. 1983, Cotinine disposition and effects. Clinical Pharmacology and Therapeutics, 34 (5), 604–611.
   Google Scholar
• BENOWITZ, N. L., HALL, S. M., HERNING, R I., JACOB, P., JONES, R T. and OSMAN, A. 1983, Smokers of low-yield cigarettes do not consume less nicotine. New England Journal of Medicine, 309 (3), 139–142.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L., LEE, B. L. and JACOB, P. 1989, Nicotine gum and theophylline metabolism. Biomedicine and Pharmacotherapy, 43, 1–3.
   PubMed Web of Science ®Google Scholar
• BENOWITZ, N. L., PEREZ-STABLE, E. J., HERRERA, B. and JACOB, P. 2002, Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. Journal of the National Cancer Institute, 94 (2), 108–115.
   Google Scholar
• BIBER, A., SCHERER, G., HOEPFNER, I., ADLKOFER, F., HELLER, W., HADDOW, J. E. and KNIGHT, G. 1987, Determination of nicotine and cotinine in human serum and urine: an interlaboratory study. Toxicology Letters, 35, 45–52.
   PubMed Web of Science ®Google Scholar
• BUTLER, M. A., LANG, N. P., YOUNG, J. F, CAPORASO, N. E., VINEIS, P., HAYES, R B., TErrEE, C. H., MASSENGILL, J. P., LAWSEN, M. F. and KADLUBAR, F F. 1992, Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmaco-genetics, 2, 116–127.
   PubMedGoogle Scholar
• CASTRO, A. and MONJI, N. 1986, Dietary nicotine and its significance in studies on tobacco smoking. Biochemical Archives, 2, 91–97.
   Google Scholar
• CURVALL, M., VALA, E. K, ENZELL, C. R. and WAHREN, J. 1990, Simulation and evaluation of nicotine intake during passive smoking: cotinine measurements in body fluid of nonsmokers given intravenous infusions of nicotine. Clinical Pharmacology and Therapeutics, 47, 42–49.
   PubMed Web of Science ®Google Scholar
• DAVIS, R A., STILEs, M. F., DEBETinzy, J. D. and RAYNOLDS, J. H. 1991, Dietary nicotine: a source of urinary cotinine. Food and Chemical Toxicology, 29 (12), 821–827.
   PubMed Web of Science ®Google Scholar
• EHRLICH, R., KATTAN, M., GODBOLD, J., SALTZBERG, D. S., GRIMM, K T., LANDRIGAN, P. J. and T ji LENFELD, D. E. 1992, Childhood asthma and passive smoking. Urinary cotinine as a biomarker of exposure. American Review of Respiratory Disease, 145 (3), 594–599.
   Google Scholar
• ELIOPOUIOS, C., KLEIN, J., PHAN, M. K., KNIE, B., GREENWALD, M., CHITAYAT, D. and KOREN, G. 1994, Hair concentrations of nicotine and cotinine in women and their newborn infants. JAMA, 271 (8), 621–623.
   PubMed Web of Science ®Google Scholar
• ELIOPOULOS, C., KLEIN, J. and KOREN, G. 1996, Validation of self-reported smoking by analysis of hair for nicotine and cotinine. Therapeutic Drug Monitoring, 18 (5), 532–536.
   PubMed Web of Science ®Google Scholar
• EREMIN, S. A., COXON, R E., COLBERT, D. L, LANDON, J. and Smrni, D. S. 1992, Urinary cotinine fluoroimmunoassay for smoking status screening adapted to an automated analyser. Analyst, 117, 697–699.
   PubMed Web of Science ®Google Scholar
• ESKENAZI, B., PREHN, A. W. and CHRISTIANSON, R. E. 1995, Passive and active maternal smoking as measured by serum cotinine: the effect on birthweight. American Journal of Public Health, 85 (3), 395–398.
   PubMed Web of Science ®Google Scholar
• ETZEL, R. A. 1990, A review of the use of saliva cotinine as a marker of tobacco smoke exposure. Preventive Medicine, 19, 190–197.
   PubMed Web of Science ®Google Scholar
• GEHLBACH, S. H., PERRY, L D., WILLIAMS, W. A. and FREEMAN, J. I. 1975, Nicotine absorption by workers harvesting green tobacco. Lancet, i, 478–480.
   Google Scholar
• GONZAI F7, Y.M., NARDIN, A. D., GROSSI, S. D., MAcHTEL E. E., GENCO, R. J. and NARDIN, E. D. 1996, Serum cotinine levels, smoking, and periodontal attachment loss. Journal of Dental Research, 75 (2), 796–802.
   Google Scholar
• HALEY, N. J. and HOFFMANN, D. 1985, Analysis for nicotine and cotinine in hair to determine cigarette smoker status. Clinical Chemistry, 31 (10), 1598–1600.
   PubMed Web of Science ®Google Scholar
• HAUFROBD, V. and LISON, D. 1998, Urinary cotinine as a tobacco-smoke exposure index: a mini review. International Archives of Occupational and Environmental Health, 71, 162–168.
   PubMed Web of Science ®Google Scholar
• HUGHES, J. R, HATSUKAMI, D. K, PICKENS, R W, KRAHN, D., MALIN, S. and LUKNIC, A. 1984, Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology, 83, 82–87.
   PubMed Web of Science ®Google Scholar
• HUGHES, J. R., HIGGINS, S. T. and BICKEL, W. K 1994, Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction, 89, 1461–1470.
   PubMed Web of Science ®Google Scholar
• JARvis, M. J., TUNSTALL-PEDOE, H., FEYERABEND, C., VESEY, C. and SALOOJEE, Y 1987, Comparison of tests used to distinguish smokers from non-smokers. American Journal of Public Health, 77 (11), 1435–1438.
   Google Scholar
• JARvis, M. J., RUSSELL, M., BENOWITZ, N. L and FEYERABEND, C. 1988, Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. American Journal of Public Health, 78 (6), 696–698.
   PubMed Web of Science ®Google Scholar
• KINTRZ, P. 1992, Gas chromotagraphic analysis of nicotine and cotinine in hair. Journal of Chromatography, 580, 347–353.
   PubMed Web of Science ®Google Scholar
• KLEIN, J. and KOREN, G. 1999, Hair analysis — a biological marker for passive smoking in pregnancy and childhood. Human and Experimental Toxicology, 18, 279–282.
   PubMed Web of Science ®Google Scholar
• KLEIN, J., FORMAN, R, EuorouLos, C. and KOREN, G. 1994, A method for simultaneous measurement of cocaine and nicotine in neonatal hair. Therapeutic Drug Monitoring, 16, 67–70.
   PubMed Web of Science ®Google Scholar
• KNIGHT, J. M., ELIOPOULOS, C., KLEIN, J., GREENWALD, M. and KOREN, G. 1998, Pharmacokinetic predisposition to nicotine from environmental tobacco smoke: a risk factor for pediatric asthma. Journal of Asthma, 35 (1), 113–117.
   PubMed Web of Science ®Google Scholar
• KOLONEN, S. A. and PUHAKAINEN, E. V. J. 1991, Assessment of automated colorimetric and the high-performance liquid chromatographic methods for nicotine intake by urine samples of smokers' smoking low- and medium-yield cigarettes. Clinica Chemica Acta, 196, 159–166.
   PubMed Web of Science ®Google Scholar
• LANDI, M. T., SINHA, R., LANG, N. P. and KADLUBAR, F. E 1999, Human cytochrome P4501A2. In Metabolic Polymorphisms and Susceptibility to Cancer, edited by P. Vineis, N. Malats, M. Lang, A. d'Errico, N. Caporaso, J. Cuzick and P. Boffetta, IARC Scientific Publications no. 148 (Lyon: IARC), pp. 173–195.
   Google Scholar
• LAWSON, G. M., HURT, R D., LOWELL, D. C., OFFORD, K. P., CROGHAN, I. T, SCHROEDER, D. R and JIANG, N. S. 1998, Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. Journal of Clinical Pharmacology, 38, 502–509.
   PubMed Web of Science ®Google Scholar
• LEQUANG, N. T, ROUSSEL, G., ROCHE, D., MIGUERES, M. L., CHRETIEN, J. and EKINDJIAN, O. G. 1994, Urine collection for nicotine and cotinine measurements in studies on nicotine addicts. Pathologk-Biologie, 42 (2), 191–196.
   PubMed Web of Science ®Google Scholar
• LODE, H. 2001, Evidence of different profiles of side effects and drug—drug interactions among the quinolones — the pharmacokinetic standpoint. Chemotherapy, 47 (3), 24–31.
   PubMed Web of Science ®Google Scholar
• MESSINA, E. S., TYNDALE, R F. and SELLERS, E. M. 1997, A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 282 (3), 1608–1614.
   PubMed Web of Science ®Google Scholar
• MILLER, L. G. 1989, Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clinical Pharmacokinetics, 17 (2), 90-108. MILLER, L. G. 1990, Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacy, 9, 125–135.
   Google Scholar
• MURPHY, S. E., JOHNSON, L. M. and PulLo, D. A. 1999, Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chemical Research in Toxicology, 12 (7), 639–645.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, M., YAMAMOTO, T, NUNOYA, K, Yowl, T, NAGASHIMA, K., INOUE, K., FUNAE, Y, SinmADA, N., KAMATAKI, T. and KUROIWA, Y. 1996, Role of human cytochrome P450 2A6 in C-oxidation of nicotine. Drug Metabolism and Disposition, 24 (11), 1212–1217.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, M., YAMAGISHI, S., YAMAMOTO, H., YAMAMOTO, T., KTJROIWA, Y. and YOKOI, T. 2000, Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clinical Pharmacology and Therapeutics, 67, 57–69.
   PubMed Web of Science ®Google Scholar
• PARAZZINI, F., DAVOLI, E., RABAIOTTI, M., RESTELLI, S., STRAMARE, L., DINDELLI, M., VECCHIA, C. L. and FANELLI, R. 1996, Validity of self-reported smoking habits in pregnancy: a saliva cotinine analysis. Acta Obstetricia et Gynecologica Scandinavica, 75, 352–354.
   PubMed Web of Science ®Google Scholar
• PEEKONEN, O., MAENPAA, J., TAAVITSAINEN, P., RAu-rio, A. and RAUNIO, H. 1998, Inhibition and induction of human cytochrome P450 (GYP) enzymes. Xenobiotica, 28 (12), 1203-1253. PEREZ-STABLE, E. J., HERRERA, B., JACOB, P. and BENowrrz, N. L. 1998, Nicotine metabolism and intake in black and white smokers. JAMA, 280 (2), 152–156.
   PubMed Web of Science ®Google Scholar
• Physicians' Desk Reference, 2001, 55th edition (Montvale: Medical Economics), p. 1614.
   Google Scholar
• PIRKLE, J. L., FLEGAL, K. M., BERNERT, J. T, BRODY, D. J., ETZEL, R A. and MAURER, K R 1996, Exposure of the US population to environmental tobacco smoke. JAMA, 275 (16), 1233–1240.
   Google Scholar
• PRITCHARD, M. P. and WOLF, C. R 2000, Other GYP: 2A6, 2B6, 4A. In Metabolic Drug Interactions, edited by R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten and M. Eichelbaum (Philadelphia: Lippincott Williams SE Wilkins), pp. 145–150.
   Google Scholar
• QUATTROCHI, L C., Vu, T. and TUKEY, R H. 1994, The human CYP1A2 gene and induction by 3-methylcholanthrene: a region of DNA that supports Ah-receptor binding and promoter-specific induction. Journal of Biological Chemistry, 269 (9), 6949–6954.
   PubMed Web of Science ®Google Scholar
• RIBOLI, E., HALEY, N. J., TREDANIEL, J., SARACCI, R, PRESTON-MARTIN, S. and TRICHOPOUI-OS, D. 1995, Misclassification of smoking status among women in relation to exposure to environmental tobacco smoke. European Respiratory Journal, 8 (2), 285–290.
   Google Scholar
• ROSA, M., PACIFICI, R., AurrERI, I., PICHINI, S., OTTAVIANI, G. and ZUCCARO, P. 1992, How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake. Clinical Pharmacology and Therapeutics, 52 (3), 324–329.
   PubMed Web of Science ®Google Scholar
• SATTOH, T, KOKUE, E. and SCHIMODA, M. 1999, The suppressive effects of lipopolysaccharide-induced acute phase response on hepatic cytochrome P450-dependent drug metabolism in rabbits. Journal of Veterinary Pharmacology and Therapeutics, 22, 87–95.
   PubMed Web of Science ®Google Scholar
• SCHEIN, J. R. 1995, Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy, 29, 1139–1148.
   PubMed Web of Science ®Google Scholar
• SCHERER, G., JARCZYK, L., HELLER, W. D., BIBER, A., NEURATH, G. B. and ADIKOFER, F. 1988, Pharmacokinetics of nicotine, cotinine and 3'-hydroxycotinine in cigarette smokers. Kinische Wochenschri 66 (11), 5–11.
   PubMed Web of Science ®Google Scholar
• SIEGMUND, B., LErrNER, E. and PFANNHAUSER, W. 1999, Determination of the nicotine content of various edible nightshades (solanaceae) and their products and estimation of the associated dietary nicotine intake. Journal of Agricultural and Food Chemistry, 47 (8), 3113–3120.
   PubMed Web of Science ®Google Scholar
• SNRT SUBCOMMITEE ON BIOCHEMICAL VERIFICATION 2002, Biochemical verification of tobacco use and cessation. Nicotine and Tobacco Research, 4, 149–159.
   PubMedGoogle Scholar
• SOFOWORA, G. G., Clio°, E. F., MAYO, G., SIR, Y. and WILKINSON, G. R 2001, In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemotherapy and Pharmacology, 47, 505–510. SWAN, G. E., HABINA, K., MEANS, B., JOBE, J. B. and EsEosrro, J. L. 1993, Saliva cotinine and recent smoking evidence for a nonlinear relationship. Public Health Reports, 108 (6), 779–783.
   Google Scholar
• UEMATSU, T. 1993, Utilization of hair analysis for therapeutic drug monitoring with a special reference to ofloxacin and to nicotine. Forensic Science International, 63, 261–268.
   PubMed Web of Science ®Google Scholar
• VINE, M. F., HUIKA, B. S., MARGOLIN, B. H., TRUONG, Y. K, Hu, P., SCHRAMM, M., GRIEErrii, J. D., MCCANN, M. and EVERSON, R. B. 1993, Cotinine concentrations in semen, urine, and blood of smokers and nonsmokers. American Journal of Public Health, 83 (9), 1335–1338.
   PubMed Web of Science ®Google Scholar
• WILLERS, S., SKARPING, G., DAI-ENE, M. and SKERFVING, S. 1995, Urinary cotinine in children and adults during and after semiexperimental exposure to environmental tobacco smoke. Archives of Environmental Health, 50 (2), 130–138.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INOUE, K., HASHIMOTO, M. and SHIMADA, T. 1999, Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology, 73, 65–70.
   PubMed Web of Science ®Google Scholar
• YEW, W. W. 2002, Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Safety, 25 (2), 111–133.
   PubMed Web of Science ®Google Scholar
• ZEVIN, S. and BENowrrz, N. L. 1999, Drug interactions with tobacco smoking. Clinical Pharmacoki-netics, 36 (6), 425–438.
   PubMed Web of Science ®Google Scholar